Johnson & Johnson (NYSE:JNJ) Position Increased by Sawgrass Asset Management LLC

Sawgrass Asset Management LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 66.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 109,395 shares of the company's stock after purchasing an additional 43,598 shares during the period. Johnson & Johnson makes up about 1.7% of Sawgrass Asset Management LLC's holdings, making the stock its 12th largest position. Sawgrass Asset Management LLC's holdings in Johnson & Johnson were worth $15,821,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in JNJ. Powers Advisory Group LLC grew its position in shares of Johnson & Johnson by 0.6% during the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock worth $1,538,000 after buying an additional 61 shares in the last quarter. Knuff & Co LLC lifted its stake in Johnson & Johnson by 0.7% during the third quarter. Knuff & Co LLC now owns 9,466 shares of the company's stock worth $1,534,000 after purchasing an additional 64 shares during the last quarter. Vertex Planning Partners LLC lifted its stake in Johnson & Johnson by 1.3% during the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company's stock worth $844,000 after purchasing an additional 65 shares during the last quarter. Freedom Day Solutions LLC lifted its stake in Johnson & Johnson by 1.1% during the third quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company's stock worth $1,016,000 after purchasing an additional 66 shares during the last quarter. Finally, Traphagen Investment Advisors LLC lifted its stake in Johnson & Johnson by 0.6% during the third quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company's stock worth $1,699,000 after purchasing an additional 67 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

Several brokerages recently issued reports on JNJ. Morgan Stanley reduced their price objective on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. Bank of America reduced their price objective on Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, January 23rd. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research note on Wednesday, December 11th. Guggenheim raised their price objective on Johnson & Johnson from $162.00 to $166.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. Finally, Barclays raised their target price on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.67.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company's stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ traded up $2.94 during trading on Wednesday, reaching $157.93. The stock had a trading volume of 7,830,622 shares, compared to its average volume of 9,018,342. The firm has a market capitalization of $380.23 billion, a price-to-earnings ratio of 23.75, a price-to-earnings-growth ratio of 2.50 and a beta of 0.52. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The stock has a 50 day moving average of $148.12 and a two-hundred day moving average of $155.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm's revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.29 earnings per share. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.14%. Johnson & Johnson's dividend payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.